"I think [cancer immunotherapy] is very exciting and ultimately will be beneficial to patients, but I do think it's blocked out a little bit of the sun at ASCO again."
Ron Squarer, CEO, Array Biopharma Inc.

"This study characterizes the extent to which our genetic makeup influences biomarkers in our blood, and it helps to define their general characteristics. With its help, we can begin to understand very comprehensively to what extent our physiological status is controlled by genetics and by nongenetic factors."
Nicole Soranzo, group leader at the Wellcome Trust Sanger Institute in Hinxton, Cambridgeshire, on a massive study exploring the ways in which common genetic variants influence the levels of various metabolites in human blood

"The decision to divest our ophthalmic business is part of our ongoing strategy to sharpen our commercial focus and improve our operational effectiveness."
Jay Galeota, president of hospital and specialty care at Merck & Co. Inc., on its decision to sell nine of its ophthalmic products to Japan-based Santen Pharmaceutical Co. Ltd.